Yin Zhang1,2,3, Kana Wu3, Andrew T Chan4,5,6,7, Jeffrey A Meyerhardt1, Edward L Giovannucci2,3,8. 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. 4. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 5. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 6. Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA. 7. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 8. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
INTRODUCTION: Statin use has been examined as a potential chemopreventive strategy against colorectal cancer (CRC). Previous studies have not been able to investigate this topic with adequate follow-up time or disentangle the effects of statin use and total cholesterol level. We investigated prospectively this topic. METHODS: Eligible participants (100,300 women and 47,991 men) in the Nurses' Health Study and Health Professionals Follow-Up Study were followed for up to 24 years. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. RESULTS: We documented 2,924 incident CRC cases during follow-up. In fully adjusted analyses, longer duration of statin use was associated with higher risk of colon cancer (hazard ratios, the 95% confidence interval was 1.09, 0.95-1.25 for 1-5 years; 1.16, 0.99-1.36 for 6-10 years; 1.08, 0.81-1.44 for 11-15 years; 1.85, 1.30-2.61 for >15 years; vs never users, P = 0.004 for trend) rather than rectal cancer. The risk elevation was driven by proximal colon cancer (1.16, 0.98-1.38 for 1-5 years; 1.19, 0.98-1.45 for 6-10 years; 1.25, 0.89-1.74 for 11-15 years; 2.17, 1.46-3.24 for >15 years; vs never users, P = 0.001 for trend) rather than distal colon cancer. The results remained robust in analyses among participants with hypercholesterolemia or who never received screening. Total cholesterol level was not associated with CRC risk. DISCUSSION: This study does not support benefit of statin use in CRC chemoprevention or any association between total cholesterol level and CRC risk. On the contrary, long-term statin use may be associated with increased colon cancer risk (driven by proximal colon cancer).
INTRODUCTION: Statin use has been examined as a potential chemopreventive strategy against colorectal cancer (CRC). Previous studies have not been able to investigate this topic with adequate follow-up time or disentangle the effects of statin use and total cholesterol level. We investigated prospectively this topic. METHODS: Eligible participants (100,300 women and 47,991 men) in the Nurses' Health Study and Health Professionals Follow-Up Study were followed for up to 24 years. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. RESULTS: We documented 2,924 incident CRC cases during follow-up. In fully adjusted analyses, longer duration of statin use was associated with higher risk of colon cancer (hazard ratios, the 95% confidence interval was 1.09, 0.95-1.25 for 1-5 years; 1.16, 0.99-1.36 for 6-10 years; 1.08, 0.81-1.44 for 11-15 years; 1.85, 1.30-2.61 for >15 years; vs never users, P = 0.004 for trend) rather than rectal cancer. The risk elevation was driven by proximal colon cancer (1.16, 0.98-1.38 for 1-5 years; 1.19, 0.98-1.45 for 6-10 years; 1.25, 0.89-1.74 for 11-15 years; 2.17, 1.46-3.24 for >15 years; vs never users, P = 0.001 for trend) rather than distal colon cancer. The results remained robust in analyses among participants with hypercholesterolemia or who never received screening. Total cholesterol level was not associated with CRC risk. DISCUSSION: This study does not support benefit of statin use in CRC chemoprevention or any association between total cholesterol level and CRC risk. On the contrary, long-term statin use may be associated with increased colon cancer risk (driven by proximal colon cancer).
Authors: Elizabeth A Platz; Michael F Leitzmann; Kala Visvanathan; Eric B Rimm; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2006-12-20 Impact factor: 13.506
Authors: Barbra A Dickerman; Xabier García-Albéniz; Roger W Logan; Spiros Denaxas; Miguel A Hernán Journal: Int J Epidemiol Date: 2020-10-01 Impact factor: 7.196
Authors: Jessica Chubak; Evelyn P Whitlock; Selvi B Williams; Aruna Kamineni; Brittany U Burda; Diana S M Buist; Melissa L Anderson Journal: Ann Intern Med Date: 2016-04-12 Impact factor: 25.391
Authors: Yin Cao; Reiko Nishihara; Kana Wu; Molin Wang; Shuji Ogino; Walter C Willett; Donna Spiegelman; Charles S Fuchs; Edward L Giovannucci; Andrew T Chan Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Yin Zhang; Mingyang Song; Andrew T Chan; Jeffrey A Meyerhardt; Walter C Willett; Edward L Giovannucci Journal: Br J Cancer Date: 2022-09-22 Impact factor: 9.075
Authors: Antonio Rodríguez-Miguel; Encarnación Fernández-Antón; Diana Barreira-Hernández; Luis A García-Rodríguez; Miguel Gil; Alberto García-Lledó; Francisco J De Abajo Journal: J Clin Med Date: 2022-03-10 Impact factor: 4.241